S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Vaccine by Johnson & Johnson Would Be a Boom for Investors… And Chances Just Increased

Monday, September 28, 2020 | Nick Vasco
Vaccine by Johnson & Johnson Would Be a Boom for Investors… And Chances Just IncreasedOn Friday, Johnson & Johnson (NYSE: JNJ) released early results from the Phase 1/2 a clinical trial for its COVID-19 vaccine. One dose appeared to produce a strong immune response in 99% of the participants. There were some mild side effects, such as fever, headache, and fatigue, but they resolved after a couple of days.

JNJ’s vaccine, called Ad26.COV2. S, is currently the only Phase 3 COVID-19 vaccine trial in the U.S. that is testing a single-dose of the vaccine.

Is JNJ Going to Win the Race for a COVID-19 Vaccine?


But either way, the company stacks up well against competitors. Moderna (NASDAQ: MRNA), for example, is ahead of JNJ in the race for a vaccine. But this may be a case of the tortoise and the hare if you dig a little deeper:

JNJ’s Ad26.COV2. S vaccine uses a proven technology that has been used for JNJ’s Ebola, Zika, HIV and RSV vaccines to vaccinate more than 180,000 people. Moderna’s mRNA technology is promising but unproven.

Johnson & Johnson was founded in 1886 and the company is a proven commodity with a long track record. On the other hand, it’s impossible to know if Moderna has the operational chops to manufacture and distribute over a billion doses of a COVID-19 vaccine – assuming it develops the vaccine first.

Of course, Moderna isn’t the only competitor for a COVID-19 vaccine. AstraZeneca Plc (NYSE: AZN) Pfizer Inc (NYSE: PFE) are just two of several others – and they are two that have much longer track records than Moderna.

 But the point is, don’t give up on JNJ’s vaccine. It could be first to market. And even if it isn’t first, it still has the potential to take market share. This isn’t a winner-take-all proposition, after all.

 And even if JNJ doesn’t make much from its COVID-19 vaccine, this is still an excellent company to invest in.

Tough Q2, But Encouraging Signs

JNJ’s Q2 numbers were down substantially yoy, but beat estimates. Revenue dipped 10.8% and net income fell 35.3%. Here are a few of the highlights:

  1. Consumer health segment sales fell 7% yoy.

 JNJ’s revenue in this segment missed expectations and the company attributed it to “consumers stocking products during the first quarter and lower consumption due to government lockdowns during the second quarter.” There was clearly a bit of a hangover after the pantry-loading craze that occurred in the early stages of the pandemic. Look for consumer health sales to even out in Q3.

  1. Worldwide medical device sales declined 32.7% to $4.3 billion.

 This fall was caused by people putting off elective procedures due to the coronavirus. The good news is that Johnson & Johnson noticed month-by-month improvement in this segment over the course of Q2. And that makes sense as people are adjusting to the new-normal and will only put off elective procedures for so long.

  1. Over-the-counter (OTC) medicines & skin, health and beauty franchise show that a lot of this is temporary.

 In Q2, sales of OTC medicines grew by 30% in the U.S., with two-thirds of the growth attributed to the pandemic. JNJ noted strong demand for Tylenol.

 The skin, health and beauty franchise sales dipped 14.3% yoy. People are going out less, which leads to less spending on skin care.

 Outlook is Mostly the Same for JNJ

JNJ is trading right around pre-pandemic levels for a reason: the long-term outlook for JNJ’s core businesses remains very similar to before.

 Another thing in the “nothing has changed” category is the dividend. JNJ has raised its dividend for each of the past 57 years. And those increases have been sizeable of late, with JNJ increasing its dividend by an annual rate of 6% over the past 10 years. Its 2.69% dividend yield is even more attractive compared to what you’ll find elsewhere.

 What has changed is the COVID-19 vaccine potential.

 And what you should do is take this as an opportunity to invest in an excellent company. A company that can offer a solid ROI if the vaccine doesn’t come to fruition – and a very nice ROI if it does.

Vaccine by Johnson & Johnson Would Be a Boom for Investors… And Chances Just Increased

Should you invest $1,000 in Johnson & Johnson right now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)
2.7937 of 5 stars
AstraZeneca (AZN)
0.8332 of 5 stars
Pfizer (PFE)
2.7905 of 5 stars
Compare These Stocks  Add These Stocks to My Watchlist 


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.